We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.395 | 1.22% | 32.735 | 32.33 | 33.33 | 33.0285 | 32.60 | 33.0285 | 31,979 | 21:29:53 |
From May 2019 to May 2024
By Giulia Petroni
Merck KGaA said Thursday that it would partner with Janssen Pharmaceutica NV to develop an artificial intelligence-based diagnostic tool for the detection of neglected tropical diseases.
The German pharmaceutical and chemicals company said the prototype that is being tested consists of an automated microscope with AI and data visualisation tool. It enables the counting of parasite eggs that develop into parasitic worms of either schistosomiasis or soil-transmitted helminthiasis.
"This automated counting process is aimed at being both faster and more reliable than the current survey method, in which a lab technician counts the eggs in each sample manually," it said.
The prototype testing is set to continue throughout the year and pass to the clinical utility testing phase in 2021 through 2023, according to Merck KGaA.
Janssen Pharmaceutica is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
July 02, 2020 05:45 ET (09:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
